Skip to content
Inciteful Med

Building Your Team: Long-Term Care and Surveillance

Last updated:

Managing Neurofibromatosis Type 1 (NF1) requires a multidisciplinary medical team typically led by a geneticist or neurologist. Long-term care involves strict surveillance, including annual physicals, routine eye exams, and sometimes a baseline whole-body MRI, to proactively monitor health.

Key Takeaways

  • • NF1 requires a multidisciplinary care team, often coordinated by a medical geneticist, neurologist, or neuro-oncologist.
  • • Standard surveillance includes annual physical exams, blood pressure checks, and routine eye exams to monitor for complications like optic gliomas.
  • • A whole-body MRI is often recommended during adolescence as a baseline to identify internal tumors that cannot be felt.
  • • Transitioning from pediatric to adult care requires early planning and education to prevent gaps in medical monitoring.

Because Neurofibromatosis Type 1 (NF1) can affect almost any part of the body, managing it requires a multidisciplinary care team—a group of specialists who work together to monitor your health from every angle [1][2]. Building this team early and sticking to a consistent surveillance schedule is the best way to ensure you or your child receives proactive, high-quality care [3].

Building Your Multidisciplinary Team

Your “home base” is often a medical geneticist, a pediatric neurologist, or an adult neuro-oncologist who specializes in NF1 [4][1]. They will help coordinate with other essential specialists, including:

  • Ophthalmologist: To monitor for vision changes and optic pathway gliomas [5].
  • Dermatologist: To track skin spots and monitor the growth of neurofibromas [1].
  • Neuropsychologist: To evaluate for learning disabilities, ADHD, Autism Spectrum Disorder (ASD), or executive function challenges [6].
  • Orthopedist: To monitor for scoliosis or bone issues like tibial dysplasia [4].
  • Oncologist: Involved if plexiform neurofibromas require medical treatment (like MEK inhibitors) or if there are concerns about malignancy [7].
  • Cardiologist/Nephrologist: To manage high blood pressure (such as from renal artery stenosis in youth, or pheochromocytoma in adults) or vascular issues if they arise [8][7].

Tip: Navigating so many different specialists can be exhausting. Consider bringing a dedicated notebook or a trusted friend to appointments to help take notes and remember instructions.

Standard Surveillance Schedule

While your doctor will tailor a plan to specific needs, general age-based surveillance typically includes:

Frequency Checkpoint Why It Matters
Annual Full Physical Exam To track growth, skin changes, and new bumps [3].
Annual Blood Pressure To catch early signs of hypertension or vascular issues [8].
Every 6–12 Months Eye Exams Critical in early childhood (up to age 7-10) to monitor for optic gliomas [5].
As Needed Whole-Body MRI Increasingly used as a “baseline” in adolescence to map internal tumor burden [9][10].
Periodic Neuropsych Testing Usually before starting school and during major transitions (e.g., middle school or early adulthood) [6].

A Note on Whole-Body MRI (WB-MRI)

Unlike a standard MRI that looks at one area (like the brain), a WB-MRI scans the entire body [11]. While it isn’t required for every person, it is the “gold standard” for identifying internal tumors that can’t be felt during a physical exam [11][12]. Many experts recommend a baseline scan as a patient enters adolescence or early adulthood [10].

Transitioning to Adult Care

One of the most critical phases in NF1 care is the transition from a pediatric team to an adult team, which typically begins in the mid-to-late teens [13].

Challenges and Solutions

  • Knowledge Gaps: Many young adults aren’t fully aware of their own medical history or the specific risks of NF1 [14]. Solution: Start using “transition readiness” tools (like the TRAQ checklist) early to teach them about their condition [15].
  • Care Gaps: Patients often “fall off the radar” once they leave their pediatrician [13]. Solution: Identify an adult NF1 specialist or a “transition clinic” before turning 18 to ensure there is no break in monitoring.
  • Psychosocial Barriers: Managing a chronic condition can be stressful for a young adult’s mental health [13]. Solution: Ensure access to counseling or support groups that focus on navigating life and body image concerns with NF1 [13].

Vetting a Specialist

When meeting a new doctor, it’s important to ensure they have specific expertise in NF1. Don’t be afraid to ask:

  1. “How many patients with NF1 do you currently follow?”
  2. “Are you familiar with the 2021 revised diagnostic criteria?”
  3. “Do you work closely with other NF1 specialists (like ophthalmologists or geneticists)?”
  4. “What is your protocol for monitoring asymptomatic tumors?”
  5. “How do you stay updated on the latest NF1 research and treatments?”

Frequently Asked Questions

What doctors should be on an NF1 care team?
An NF1 care team is usually led by a medical geneticist, pediatric neurologist, or adult neuro-oncologist. It often includes an ophthalmologist for eye health, a dermatologist for skin spots, and other specialists like orthopedists or neuropsychologists depending on your specific needs.
How often should someone with NF1 see their doctor?
Most patients with NF1 need an annual full physical exam and blood pressure check. Children typically require eye exams every 6 to 12 months to monitor for optic gliomas, and your doctor may recommend other periodic tests like neuropsychological evaluations or MRI scans.
What is a whole-body MRI and why is it used for NF1?
A whole-body MRI is an imaging scan that looks at the entire body rather than just one area. It is considered the gold standard for identifying internal tumors that cannot be felt during a regular physical exam, and is often done as a baseline during adolescence.
How do patients with NF1 transition from pediatric to adult care?
Transitioning involves identifying an adult NF1 specialist or transition clinic before turning 18 to avoid gaps in medical monitoring. It also involves teaching the young adult about their medical history and the specific risks associated with NF1 so they can actively manage their own health.

Questions for Your Doctor

  • • How many patients with NF1 do you currently treat, and what is your experience with its specific complications?
  • • Who is the main point of contact or 'care coordinator' on my or my child's multidisciplinary team?
  • • What is your specific protocol for eye exams and blood pressure monitoring for someone my or my child’s age?
  • • When do you typically recommend a 'baseline' whole-body MRI, and what exactly would that tell us?
  • • At what age does your clinic begin the process of transitioning a patient from pediatric to adult care, and how do you facilitate that?

Questions for You

  • • How am I tracking various appointments and test results? Is there a digital tool or binder that works best for me?
  • • Which specialist do I or my child feel most comfortable with, and why? How can we build on that relationship?
  • • What are the specific educational, social, or occupational goals, and has the school or workplace been looped into the care plan?
  • • As I or my child grow older, what small steps can be taken to manage health independently (e.g., describing symptoms directly to the doctor)?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Orthopaedic manifestations of neurofibromatosis type 1: A case report.

    Năstase F, Radaschin DS, Niculeț E, et al.

    Experimental and therapeutic medicine 2022; (23(2)):135 doi:10.3892/etm.2021.11058.

    PMID: 35069816
  2. 2

    Role, function and challenges of multidisciplinary centres for rare diseases exemplified for neurofibromatosis type 1 syndrome.

    Toledano-Alhadef H, Mautner VF, Gugel I, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(10)):2279-2284 doi:10.1007/s00381-020-04708-1.

    PMID: 32514759
  3. 3

    Neurofibromatosis 1 (von Recklinghausen Disease).

    Yoshida Y

    The Keio journal of medicine 2025; (74(1)):37-41 doi:10.2302/kjm.2023-0013-IR.

    PMID: 37635082
  4. 4

    Neurofibromatosis type 1.

    Anderson JL, Gutmann DH

    Handbook of clinical neurology 2015; (132()):75-86.

    PMID: 26564071
  5. 5

    An Isolated Case of Unilateral Macro-Ophthalmia With Resultant Anisometropic Amblyopia in Neurofibromatosis 1.

    Mukit FA, Cape HT, Huq SS, Bohn S

    Cureus 2023; (15(9)):e44679 doi:10.7759/cureus.44679.

    PMID: 37809258
  6. 6

    Editorial: Understanding the Nature of Attention Problems in Neurofibromatosis Type 1: Clinical and Research Implications.

    Vogel AC

    Journal of the American Academy of Child and Adolescent Psychiatry 2025; (64(4)):419-420 doi:10.1016/j.jaac.2024.12.005.

    PMID: 39722341
  7. 7

    Spontaneous Tension Hemothorax in a Patient With Neurofibromatosis Type 1.

    Koike Y, Kousen D, Kurinobu T, Shimizu K

    Cureus 2024; (16(10)):e71486 doi:10.7759/cureus.71486.

    PMID: 39411370
  8. 8

    Screening for Hereditary Pheochromocytoma in a Patient with Neurofibromatosis Type 1: A Case Report.

    Ferreira Barros II, Manso F, Caldas E Silva AI, Silva Lopes Pereira MR

    TouchREVIEWS in endocrinology 2021; (17(1)):79-82 doi:10.17925/EE.2021.17.1.79.

    PMID: 35118451
  9. 9

    Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.

    Ahlawat S, Fayad LM, Khan MS, et al.

    Neurology 2016; (87(7 Suppl 1)):S31-9 doi:10.1212/WNL.0000000000002929.

    PMID: 27527647
  10. 10

    Whole-body MRI-based long-term evaluation of pediatric NF1 patients without initial tumor burden with evidence of newly developed peripheral nerve sheath tumors.

    Schmalhofer ML, Farschtschi S, Kluwe L, et al.

    Orphanet journal of rare diseases 2024; (19(1)):412 doi:10.1186/s13023-024-03420-6.

    PMID: 39497113
  11. 11

    Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

    Salamon J, Mautner VF, Adam G, Derlin T

    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin 2015; (187(12)):1084-92 doi:10.1055/s-0035-1553505.

    PMID: 26333104
  12. 12

    Clinical characterization of children and adolescents with NF1 microdeletions.

    Kehrer-Sawatzki H, Kluwe L, Salamon J, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2020; (36(10)):2297-2310 doi:10.1007/s00381-020-04717-0.

    PMID: 32533297
  13. 13

    Transition to adult care of young patients with neurofibromatosis type 1 and cognitive deficits: a single-centre study.

    Lausdahl S, Handrup MM, Rubak SL, et al.

    Orphanet journal of rare diseases 2022; (17(1)):208 doi:10.1186/s13023-022-02356-z.

    PMID: 35597953
  14. 14

    Transition Readiness Assessment in Adolescents and Young Adults with Neurofibromatosis Type 1 (NF1).

    Goetsch Weisman A, Haws T, Lee J, et al.

    Comprehensive child and adolescent nursing 2023; (46(3)):223-239 doi:10.1080/24694193.2020.1806402.

    PMID: 32969737
  15. 15

    Perceived transition readiness among adolescents and young adults with neurofibromatosis type 1 and plexiform neurofibromas: a cross-sectional descriptive study.

    Siegel A, Lockridge R, Struemph KL, et al.

    Journal of pediatric psychology 2024; (49(6)):383-391 doi:10.1093/jpepsy/jsae006.

    PMID: 38366576

This page provides general information about building a multidisciplinary care team for Neurofibromatosis Type 1 (NF1). It does not replace professional medical advice, and you should always consult your doctors about your specific surveillance schedule.

Stay up to date

Get notified when new research about Neurofibromatosis type 1 is published.

No spam. Unsubscribe anytime.